Cambridge Investment Research Advisors, Inc. Recursion Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $27.1 Billion
- Q2 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 76,968 shares of RXRX stock, worth $474,892. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76,968
Previous 70,110
9.78%
Holding current value
$474,892
Previous $699,000
17.45%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding RXRX
# of Institutions
285Shares Held
236MCall Options Held
972KPut Options Held
2.4M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl28.1MShares$174 Million1.92% of portfolio
-
Baillie Gifford & CO26.6MShares$164 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA21.6MShares$133 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$107 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$94.9 Million1.74% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.11B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...